Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.28 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 180 | 0.91 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 1417
Sealed predictions
- IKZF2 in dopamine neurons, braak-0.03 (p 0.944) → +0.02 (p 0.962)receipt 1425
Swarm cases
receipt 1425: IKZF2 in dopamine neurons, braak
- power
- full sample +0.07 (p 0.794, n 18), 95% CI -0.41 to +0.52. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.06 (p 0.820, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.06 (p 0.814, n 18). could be the mix.
- skeptic
- leave-one-out range -0.05 to +0.19, sign flips 3; without severely affected donors +0.07 (p 0.794, n 18). fragile.
- cell type
- strongest in microglia: +0.63 (p 0.0051, n 18) vs +0.07 in dopamine neurons. proposing microglia.
- axis
- no measure beats "tracks Braak Lewy-body stage" for IKZF2 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up IKZF2 · microglia · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.30 p 0.286 (needs p < 9.8e-4)
Receipts
loading the receipts